Business Wire Feed
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028VENLO, Netherlands--(BUSINESS WIRE)--$QGEN #QIAGEN--QIAGEN N.V. (NYSE: more...
Oxford Nanopore Receives Regulatory Approval for its First Diagnostic Device in the UK and Europe
Oxford Nanopore has reached a major regulatory milestone with the registration of its first In Vitro Diagnostic (“IVD”) device in the UK and Europe: the GridION™ Dx.OXFORD, England--(BUSINESS WIRE)--#Nanopore--Oxford Nanopore Technologies today announces that the more...
ChemWerth Appoints New General Sales Manager To Increase Its Generic API Footprint in India
WOODBRIDGE, Conn.--(BUSINESS WIRE)--ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market. To support its growth in the more...
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
2025 revenues are expected to increase by approximately 35% compared to 2024, which is approximately $40 million above the top end of Natera’s financial outlook Additional business updates will be presented at the 44th Annual more...
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
Reported preliminary, unaudited Data and application revenue of ~$316 million for the full year 2025, representing ~31% year-over-year growth, with Insights (data licensing) growing 38% 2025 Net revenue retention of ~126%CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: more...
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487 Million (103% Growth vs. 2024) – − Company Provides 2026 Combined more...
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. more...
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January more...
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion – – Presentation more...
Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without bevacizumab The BREAKWATER study demonstrates clinically more...
MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
Validated Across Influenza A and Influenza B, Including H3N2 Subclade K and Zoonotic Influenza A Subtypes H5, H7, H9AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology more...
Edwards Comments on JenaValve Acquisition
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company’s more...
Healthpeak Properties Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, is scheduled to report fourth quarter 2025 financial results after the close of trading on more...
Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial
Peer-reviewed publication in “The Oncologist” is now available online Investigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day dosingLAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) more...
IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026, before the more...
Dentalcorp Announces Receipt of Investment Canada Act Approval and Expected Closing Date for Acquisition by Investment Funds Affiliated with GTCR
TORONTO--(BUSINESS WIRE)--dentalcorp Holdings Ltd. (“Dentalcorp” or the “Company”) (TSX: DNTL) announced today that the Company has received approval under the Investment Canada Act for its previously-announced plan of arrangement whereby a newly formed acquisition vehicle more...
PharmaJet’s Needle-free Injection System Selected to Administer DNA Immunotherapy for Advanced Melanoma in Late-stage Clinical Development following Positive Phase 2 Data
PharmaJet’s intramuscular (IM) Needle-free Injection System - Stratis® - was used to deliver Scancell’s iSCIB1+ DNA immunotherapy in combination with immune checkpoint inhibitors in the SCOPE Phase 2 trial. The Scancell immunotherapy delivered using PharmaJet’s more...
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease
Collaboration supports pre-IND development activities and establishes a structured path for potential next-stage development and commercializationWASHINGTON--(BUSINESS WIRE)--KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into more...
BCG and Hippocratic AI Announce Strategic Collaboration to Deploy Agentic AI Across Biopharma and Medtech
Partnership accelerates real-world generative AI value creation in biopharma and medtech industries.SAN FRANCISCO--(BUSINESS WIRE)--#GenAI--Boston Consulting Group (BCG) and Hippocratic AI today announced a global collaboration aimed at transforming the biopharma and medtech industries through the more...
Jupiter Medical Center and Hospital for Special Surgery Join Forces to Advance Orthopedic Care in South Florida
JUPITER, Fla.--(BUSINESS WIRE)--Jupiter Medical Center (JMC) and Hospital for Special Surgery (HSS) are teaming up to expand access to the highest quality musculoskeletal care in South Florida. The alliance brings together Jupiter Medical Center, the more...
Amazon Pharmacy Expands Access to New Wegovy® Pill with Insurance and Cash-Pay Options
Amazon Pharmacy now offers Novo Nordisk’s newly FDA-approved oral GLP-1 with transparent pricing and fast, free home deliverySEATTLE--(BUSINESS WIRE)--Amazon Pharmacy (NASDAQ: AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, now offers more...
City of Hope Appoints Veteran Life Sciences Leader Vanessa Almendro Navarro as Chief Commercialization Officer
LOS ANGELES--(BUSINESS WIRE)--City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. more...
Real Chemistry Establishes RC Resolve, an Advisory Practice for Healthcare’s Most Critical Business, Regulatory and Value Inflection Points
Healthcare veterans from biopharma industry, agency and advisory firms will deliver tech-enabled insight, influence and actionNEW YORK--(BUSINESS WIRE)--Real Chemistry today announced the launch of RC Resolve, a healthcare advisory practice designed to help leaders navigate more...
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offeringWALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s more...
Naveris® to Highlight New Publications at the 44th Annual J.P. Morgan Healthcare Conference
Recent Peer-Reviewed Data Reinforces Value of Molecular Residual Disease Testing in Head and Neck Cancer and Anal Cancer Surveillance ProtocolsDURHAM, N.C.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-driven cancers, today announced that more...